Genome Editing: Technologies and Global Markets

This report analyzes the market for genome editing technologies, applications and end users, offering insights into the market and technological trends. The study focuses on technologies such as CRISPR-Cas, transcription activator-like effector nucleases (TALEN) and zinc finger nucleases (ZFN), assessing their adoption in biopharmaceutical, agricultural biotech and research sectors. The market is segmented by applications into drug development, plant breeding, diagnostics and clinical therapy.

The report provides an analysis covering the regions of North America, Europe, Asia-Pacific and the Rest of the World (RoW), which includes Latin America, the Middle East and Africa. It evaluates the drivers, restraints, opportunities and challenges affecting the market and vendor landscape. It discusses clinical trials, patents and emerging technologies related to the market and looks at ESG-related developments.

The study offers an analysis of the competitive landscape, which ranks the top companies in the global market for genome editing. It also has a section with company profiles covering details of the market leaders. For market estimates, data has been provided for 2022 and 2023 as the historic years, 2024 as the base year, and forecasts for 2025 to 2030.

Report Includes

52 data tables and 58 additional tables
A review of the global market for genome editing technologies
Analyses of the global market trends, with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
Evaluation and forecast of the genome editing market, and a corresponding market share analysis by product, application, end user and geographic region
In-depth facts and figures concerning market drivers and deterrents, and other macroeconomic forces influencing the genome editing market
A look at the use of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and how it has fueled the growth of the genome editing industry
An evaluation of the recent technological breakthroughs and issues, market regulations, and the current status of the intellectual property rights of the CRISPR-Cas9 genome editing technology
Review of patent trends and research publications in the global genome editing industry
Insight into the industry structure, competitive landscape, R&D activity, growth strategies and ESG trends
Identification of the companies best positioned to meet market demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
Profiles of the leading companies, includin;Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics, and Cellectis S.A.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview and Market Definition
Macroeconomic Factors
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Prevalence of Genetic Disorders
New Genome-Editing Technologies and Applications
Increasing Government and Private Funding
Market Restraints
Governmental Policies and Regulations
Ethical and Societal Concerns
Market Opportunities
Expanding Applications for CRISPR Technology
Applications in Plant and Livestock Breeding
Market Challenges
Scalability Constraints in Gene Editing Workflows
Cost of CRISPR-based Therapy

Chapter 4 Regulatory Landscape

Regulatory Scenario, by Country/Region
North America
EU
Asia-Pacific
Rest of the World

Chapter 5 Emerging Technologies and Developments

Emerging Technologies
In Vivo Delivery of CRISPR
Improved Cas Variants
Artificial Intelligence
Takeaways: Emerging Technologies in CRISPR
Clinical Trials Analysis
Clinical Trials Analysis, by Type of Study
Clinical Trials Analysis, by Status
Clinical Trials Analysis, by Phase
Selected Clinical Trials
Takeaways: Clinical Trials Landscape
Patent Analysis
Patents, by Year
Patents, by Leading Applicant
Patents, by Leading Patent Holder
Recent Patents Relating to Genome Editing Technology
IP Disputes and Patent Issues
Key Takeaways: Patent Landscape (2020-2024)

Chapter 6 Market Segment Analysis

Segmentation Breakdown
Global Genome Editing Market, by Technology Type
CRISPR-Cas
TALEN
ZFNs
Other Genome Editing Platforms
Global Genome Editing Market, by Application
Drug Development
Plant Breeding
Diagnostics
Clinical Therapy
Other Applications
Global Genome Editing Market, by End User
Biopharmaceutical Companies
Agricultural Biotechnology
Research Institutions
Other End Users
Geographic Breakdown
Global Genome Editing Market, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Market Ranking Analysis
Strategic Analysis
Final Takeaways

Chapter 8 Sustainability in the Genome Editing Market: ESG Perspective

Introduction to ESG
Sustainability in Genome Editing: An ESG Perspective
ESG Issues
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks

Chapter 9 Appendix

Methodology
References
Abbreviations
Company Profiles
AGILENT TECHNOLOGIES INC.
BEAM THERAPEUTICS
CARIBOU BIOSCIENCES INC.
CELLECTIS S.A.
CRISPR THERAPEUTICS
EDITAS MEDICINE
GENSCRIPT
INTELLIA THERAPEUTICS INC.
MERCK KGAA
ORIGENE TECHNOLOGIES INC.
PRECISION BIOSCIENCES
SANGAMO THERAPEUTICS
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
VERVE THERAPEUTICS INC.

List of Tables

Summary Table: Global Market for Genome Editing, by Technology, Through 2030
Table 1: CRISPR-based Therapies for Genetic Diseases
Table 2: Asia-Pacific Regulatory Landscape
Table 3: RoW Regulatory Landscape
Table 4: Clinical Trials in CRISPR Technology, by Type of Study
Table 5: Clinical Trials for CRISPR Technology, by Status, as of August 2024
Table 6: Clinical Trials for CRISPR Technology, by Phase, as of August 2024
Table 7: Clinical Trials, 2024
Table 8: Most CRISPR Technology Patents, by Applicant, 2020-2024
Table 9: Leading Patent Holders for CRISPR Technology, by Number of Patents, 2020-2024
Table 10: Genome Editing Technology Patents Filed, 2024 and 2025
Table 11: Global Market for Genome Editing, by Technology, Through 2030
Table 12: Global Market for CRISPR-Cas Genome Editing Technology, by Region, Through 2030
Table 13: Global Market for TALEN Genome Editing Technology, by Region, Through 2030
Table 14: Global Market for ZFN Genome Editing Technology, by Region, Through 2030
Table 15: Global Market for Other Genome Editing Technologies, by Region, Through 2030
Table 16: Global Market for Genome Editing, by Application, Through 2030
Table 17: Global Market for Genome Editing in Drug Development, by Region, Through 2030
Table 18: Global Market for Genome Editing in Plant Breeding, by Region, Through 2030
Table 19: Global Market for Genome Editing in Diagnostics, by Region, Through 2030
Table 20: Global Market for Genome Editing in Clinical Therapy, by Region, Through 2030
Table 21: Global Market for Genome Editing in Other Applications, by Region, Through 2030
Table 22: Global Market for Genome Editing, by End User, Through 2030
Table 23: Global Market for Genome Editing for Biopharmaceuticals, by Region, Through 2030
Table 24: Global Market for Genome Editing for Agricultural Biotechnology, by Region, Through 2030
Table 25: Global Market for Genome Editing for Research Institutions, by Region, Through 2030
Table 26: Global Market for Genome Editing for Other End Users, by Region, Through 2030
Table 27: Global Market for Genome Editing, by Region, Through 2030
Table 28: North American Market for Genome Editing, by Country, Through 2030
Table 29: North American Market for Genome Editing, by Technology, Through 2030
Table 30: North American Market for Genome Editing, by Application, Through 2030
Table 31: North American Market for Genome Editing, by End User, Through 2030
Table 32: European Market for Genome Editing, by Country, Through 2030
Table 33: European Market for Genome Editing, by Technology, Through 2030
Table 34: European Market for Genome Editing, by Application, Through 2030
Table 35: European Market for Genome Editing, by End User, Through 2030
Table 36: Asia-Pacific Market for Genome Editing, by Country, Through 2030
Table 37: Asia-Pacific Market for Genome Editing, by Technology, Through 2030
Table 38: Asia-Pacific Market for Genome Editing, by Application, Through 2030
Table 39: Asia-Pacific Market for Genome Editing, by End User, Through 2030
Table 40: RoW Market for Genome Editing, by Technology, Through 2030
Table 41: RoW Market for Genome Editing, by Application, Through 2030
Table 42: RoW Market for Genome Editing, by End User, Through 2030
Table 43: Ranking of Genome Editing Companies
Table 44: CRISPR Technology Companies
Table 45: Recent Developments in the CRISPR Technology Industry, 2022-2025
Table 46: Bioethical Issues and Risks Associated with CRISPR Technology
Table 47: ESG Rankings for Genome Editing Companies, 2024*
Table 48: ESG: Environmental Overview
Table 49: ESG: Social Overview
Table 50: ESG: Governance Overview
Table 51: Information Sources for this Report
Table 52: Abbreviations Used in this Report
Table 53: Agilent Technologies Inc.: Company Snapshot
Table 54: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 55: Agilent Technologies Inc.: Product Portfolio
Table 56: Agilent Technologies Inc.: News/Key Developments, 2024
Table 57: Beam Therapeutics: Company Snapshot
Table 58: Beam Therapeutics: Financial Performance, FY 2023 and 2024
Table 59: Beam Therapeutics: Product Portfolio
Table 60: Beam Therapeutics: News/Key Developments, 2021-2023
Table 61: Caribou Biosciences Inc.: Company Snapshot
Table 62: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 63: Caribou Biosciences Inc.: Product Portfolio
Table 64: Caribou Biosciences Inc.: News/Key Developments, 2021-2023
Table 65: Cellectis S.A.: Company Snapshot
Table 66: Cellectis S.A.: Financial Performance, FY 2023 and 2024
Table 67: Cellectis S.A.: Product Portfolio
Table 68: Cellectis S.A.: News/Key Developments, 2021-2024
Table 69: CRISPR Therapeutics: Company Snapshot
Table 70: CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
Table 71: CRISPR Therapeutics: Product Portfolio
Table 72: CRISPR Therapeutics: News/Key Developments, 2021-2024
Table 73: Editas Medicine: Company Snapshot
Table 74: Editas Medicine: Financial Performance, FY 2023 and 2024
Table 75: Editas Medicine: Product Portfolio
Table 76: Editas Medicine: News/Key Developments, 2024 and 2025
Table 77: GenScript: Company Snapshot
Table 78: GenScript: Financial Performance, FY 2023 and 2024
Table 79: GenScript: Product Portfolio
Table 80: GenScript: News/Key Developments, 2022 and 2023
Table 81: Intellia Therapeutics Inc.: Company Snapshot
Table 82: Intellia Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 83: Intellia Therapeutics Inc.: Product Portfolio
Table 84: Merck KGaA: Company Snapshot
Table 85: Merck KGaA: Financial Performance, FY 2023 and 2024
Table 86: Merck KGaA: Product Portfolio
Table 87: Merck KGaA: News/Key Developments, 2021 and 2024
Table 88: Origene Technologies Inc.: Company Snapshot
Table 89: Origene Technologies Inc.: Product Portfolio
Table 90: Precision BioSciences: Company Snapshot
Table 91: Precision BioSciences: Financial Performance, FY 2023 and 2024
Table 92: Precision BioSciences: Product Portfolio
Table 93: Precision BioSciences: News/Key Developments, 2022 and 2025
Table 94: Sangamo Therapeutics: Company Snapshot
Table 95: Sangamo Therapeutics: Financial Performance, FY 2023 and 2024
Table 96: Sangamo Therapeutics: Product Portfolio
Table 97: Sangamo Therapeutics: News/Key Developments, 2024
Table 98: Takara Bio Inc.: Company Snapshot
Table 99: Takara Bio Inc.: Financial Performance, FY 2023 and 2024
Table 100: Takara Bio Inc.: Product Portfolio
Table 101: Takara Bio Inc.: News/Key Developments, 2024
Table 102: Thermo Fisher Scientific Inc.: Company Snapshot
Table 103: Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 104: Thermo Fisher Scientific Inc: Product Portfolio
Table 105: Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022
Table 106: Verve Therapeutics Inc.: Company Snapshot
Table 107: Verve Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 108: Verve Therapeutics Inc.: Product Portfolio
Table 109: Verve Therapeutics Inc.: News/Key Developments, 2024 and 2025

List of Figures

Summary Figure: Global Market Shares of Genome Editing, by Technology, 2024
Figure 1: Porter’s Five Forces Analysis for the Genome Editing Market
Figure 2: Market Dynamics Snapshot
Figure 3: Emerging Trends/Technologies in the CRISPR Market
Figure 4: Patents Granted Related to CRISPR Technology, by Year, 2020-2024
Figure 5: Global Market Shares of Genome Editing, by Technology, 2024
Figure 6: Workflow for CRISPR Gene Editing
Figure 7: Global Market Shares of Genome Editing, by Application, 2024
Figure 8: Global Market Shares of Genome Editing, by End User, 2024
Figure 9: Global Market Shares of Genome Editing, by Region, 2024
Figure 10: North American Market Shares of Genome Editing, by Country, 2024
Figure 11: European Market Shares of Genome Editing, by Country, 2024
Figure 12: Asia-Pacific Market Shares of Genome Editing, by Country, 2024
Figure 13: ESG Pillars
Figure 14: Advantages of ESG
Figure 15: Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 16: Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 17: GenScript: Revenue Shares, by Business Unit, FY 2024
Figure 18: GenScript: Revenue Shares, by Country/Region, FY 2024
Figure 19: Merck KGaA: Revenue Shares, by Business Unit, FY 2024
Figure 20: Merck KGaA: Revenue Shares, by Country/Region, FY 2024
Figure 21: Takara Bio Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 22: Takara Bio Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 23: Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 24: Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2024

Executive Summary

The global market for genome editing is expected to grow from $10.8 billion in 2025 and is projected to reach $23.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.9% during the forecast period of 2025 to 2030.

The global market for genome editing is fueled by advances in genetic engineering technologies, growing demand for targeted therapeutics, and the increasing integration of genomics into clinical and agricultural applications. Genome editing tools—such as CRISPR-Cas systems, TALENs, ZFNs, and emerging platforms like base and prime editing—are revolutionizing how scientists and clinicians manipulate DNA to correct genetic defects, engineer desirable traits and develop novel therapeutics. These technologies are increasingly used in drug development, clinical therapy, diagnostics, plant breeding and biomedical research, due to their precision, efficiency and cost-effectiveness.

Companies Mentioned

Agilent Technologies Inc.
Beam Therapeutics
Caribou Biosciences Inc.
Cellectis S.A.
Crispr Therapeutics
Editas Medicine
Genscript
Intellia Therapeutics Inc.
Merck Kgaa
Origene Technologies Inc.
Precision Biosciences
Sangamo Therapeutics
Takara Bio Inc.
Thermo Fisher Scientific Inc.
Verve Therapeutics Inc.

Table Information

Report Attribute	Details
No. of Pages	117
Published	July 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 10.8 Billion
Forecasted Market Value ( USD ) by 2030	$ 23.7 Billion
Compound Annual Growth Rate	16.9%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4159EUR$4,650USD£3,659GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€4991EUR$5,580USD£4,390GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5989EUR$6,696USD£5,268GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€7187EUR$8,035USD£6,322GBP

Report Includes

Table of Contents

Executive Summary

Companies Mentioned

Table Information

Related Topics

Related Reports

Meganuclease Genome Editing Market Report 2025

Genome Editing Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

Genome Editing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Genome Editing/Genome Engineering Market Report 2025

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-in), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029